{
    "root": "695c03ee-2c4f-44a7-aaca-bb41fdaa9dca",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Qfitlia",
    "value": "20250326",
    "ingredients": [
        {
            "name": "FITUSIRAN",
            "code": "SV9W47ZLE1",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15002"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE",
            "code": "70WT22SF4B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE",
            "code": "593YOG76RN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "PHOSPHORIC ACID",
            "code": "E4GA8884NN",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26078"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        }
    ],
    "indications": {
        "text": "qfitlia indicated routine prophylaxis prevent reduce frequency bleeding episodes adult pediatric patients aged 12 years older hemophilia b without factor viii ix inhibitors .",
        "doid_entities": [
            {
                "text": "hemophilia (DOID:0061030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0061030"
            },
            {
                "text": "hemophilia b (DOID:12259)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12259"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "subcutaneous . starting dose : 50 mg every 2 months ( 2.1 ) . monitor activity using fda-cleared test . maintain activity 15\u201335 % adjusting dose and/or frequency ( 2.2 ) . full prescribing information important preparation instructions ( 2.4 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors.",
    "contraindications_original": "For subcutaneous use only. Starting dose: 50 mg once every 2 months ( 2.1 ). Monitor AT activity using an FDA-cleared test. Maintain AT activity between 15\u201335% by adjusting the dose and/or frequency of administration ( 2.2 ). See Full Prescribing Information for important preparation and administration instructions ( 2.4 ).",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Qfitlia",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15002"
        }
    ]
}